Table 2 Comparison of prognostic information for MFS
Patient group | All | TN | HER2+ | HR+/HER2− | |
|---|---|---|---|---|---|
N° patients | 3046 | 563 | 352 | 2131 | |
N° distant Evt | 631 | 143 | 97 | 391 | |
Clinical model | LR-X² | 75.00 | --- | --- | 45.45 |
p-Value | 3.84E–14 | --- | --- | 3.21E–09 | |
ICR classification | LR-X² | 10.57 | 15.38 | 12.19 | 1.66 |
p-Value | 1.15E–03 | 8.79E–05 | 4.81E–04 | 0.198 | |
70-gene signature | LR-X² | 72.09 | 0.11 | 1.08 | 55.09 |
p-Value | < 2.00E–16 | 0.735 | 0.298 | 1.15E–13 | |
Clinical + 70-gene + ICR4 | LR-X² | 90.2 | 15.41 | 12.66 | 61.01 |
p-Value | < 2.00E–16 | 4.51E–04 | 1.78E-03 | 2.81E–11 | |
Clinical + 70-gene + ICR4 vs. Clinical + 70-gene | LR-ΔX² | 10.31 | 15.30 | 11.57 | 3.78 |
p-Value | 1.33E–03 | 9.19E–05 | 6.69E–04 | 0.052 | |
Recurrence score (RS) | LR-X² | 73.76 | 0.53 | 2.35 | 38.44 |
p-Value | 1.11E–16 | 0.769 | 0.309 | 4.49E–09 | |
Clinical + RS + ICR4 | LR-X² | 110.90 | 16.20 | 15.06 | 75.67 |
p-Value | < 2.00E–16 | 1.03E–03 | 1.76E–03 | 1.05E–13 | |
Clinical + RS + ICR4 vs. Clinical + RS | LR-ΔX² | 10.39 | 15.68 | 12.72 | 4.46 |
p-Value | 1.27E–03 | 7.52E–05 | 3.63E–04 | 3.46E–02 | |
Risk of relapse (ROR-P) | LR-X² | 103.20 | 0.65 | 3.02 | 77.38 |
p-Value | < 2.00E–16 | 0.723 | 0.221 | < 2.00E–16 | |
Clinical + ROR-P + ICR4 | LR-X² | 106.5 | 16.12 | 16.11 | 74.18 |
p-Value | < 2.00E–16 | 1.07E–03 | 1.08E–03 | 2.10E–13 | |
Clinical + ROR-P + ICR4 vs. Clinical + ROR-P | LR-ΔX² | 12.41 | 15.47 | 13.09 | 5.77 |
p-Value | 4.27E–04 | 8.38E–05 | 2.97E–04 | 1.63E–02 | |
* Clinical model variables | pT, grade & HR mRNA | none | none | pT & grade | |
